Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutation

Supporters

Support the authors with ResearchCoin

Tip RSC

Preprint Server

Topics

Biology

Cancer Oncology

Medicine

Internal Medicine

Kras

Show all topics

DOI

10.1101/2023.09.13.557593

License

CC-BY-NC-ND

Other Formats

PDF